Abstract: A central role for the gene encoding dopamine beta-hydroxylase in neuropsychiatric disorders is disclosed. Use of single nucleotide polymorphisms in the dopamine beta-hydroxylase gene for diagnosis, prediction of clinical course and treatment response, development of new treatments and development of cell-culture based and animal models for research and treatment are disclosed.

Abstract: An array of oligonucleotides on a solid substrate is disclosed, which can be used for multiple purposes. Methods and reagents are provided for performing genotyping to determine the identity or ratio of allelic forms of a gene in a sample. A single base extension primer is coupled to a sequence identity code. During the primer extension reaction a distinctive label is incorporated which identifies the allelic form present in the sample. This permits multiple simultaneous analyses to be performed easily and efficiently.

Abstract: Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as bipolar disorder.

Abstract: Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as bipolar disorder.

Abstract: The disclosure relates to methods of diagnosing psychiatric disorders (e.g., schizophrenia, bipolar disorder), methods of classifying a sample as derived from an individual having a psychiatric disorder, methods of identifying compounds for use in modulating psychiatric disorders, methods of modulating psychiatric disorders and methods of assessing efficacy of treatment of psychiatric disorders. The disclosure also relates to oligonucleotide microarrays containing probes for genes which are differentially expressed between schizophrenic individuals and normal individuals and to oligonucleotide microarrays containing probes for genes which are differentially expressed between bipolar individuals and normal individuals. The disclosure also relates to methods of classifying a sample as a pre-frontal cortex and/or cerebellum sample, as well as to oligonucleotide microarrays containing probes for genes which are differentially expressed in pre-frontal cortex and cerebellum.

Abstract: A central role for the gene encoding dopamine beta-hydroxylase in neuropsychiatric disorders is disclosed. Use of single nucleotide polymorphisms in the dopamine beta-hydroxylase gene for diagnosis, prediction of clinical course and treatment response, development of new treatments and development of cell-culture based and animal models for research and treatment are disclosed.

Abstract: Methods for diagnosing and treating neuropsychiatric disorders, especially schizophrenia, and methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as schizophrenia.

Abstract: Methods for diagnosing and treating neuropsychiatric disorders, especially bipolar disorder, and to methods for identifying compounds for use in the diagnosis and treatment of neuropsychiatric disorders are disclosed. Also disclosed are novel compounds and pharmaceutical compositions for use in the diagnosis and treatment of neuropsychiatric disorders such as bipolar disorder.

Abstract: Methods for selecting primers having a reduced incidence of undesirable interactions are disclosed. Methods of improving the accuracy of SBE-fluorescence polarization (SBE-FP) methods are also disclosed.